Cargando…

Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients

Background: Alopecia areata (AA) is associated with Interferon- γ (IFN-γ) mediated T-lymphocyte dysfunction and increased circulating Interleukine-17 (IL-17) levels. Epigallocatechin-3-gallate (EGCG) specifically inhibits IFN-γ pathways and unlike Janus Kinase 1 and 2 (JAK1/JAK2) inhibitors (tofacit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamed, Fatma N., McDonagh, Andrew J. G., Almaghrabi, Sarah, Bakri, Youssef, Messenger, Andrew G., Tazi-Ahnini, Rachid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313664/
https://www.ncbi.nlm.nih.gov/pubmed/30558329
http://dx.doi.org/10.3390/ijerph15122882
_version_ 1783383985294934016
author Hamed, Fatma N.
McDonagh, Andrew J. G.
Almaghrabi, Sarah
Bakri, Youssef
Messenger, Andrew G.
Tazi-Ahnini, Rachid
author_facet Hamed, Fatma N.
McDonagh, Andrew J. G.
Almaghrabi, Sarah
Bakri, Youssef
Messenger, Andrew G.
Tazi-Ahnini, Rachid
author_sort Hamed, Fatma N.
collection PubMed
description Background: Alopecia areata (AA) is associated with Interferon- γ (IFN-γ) mediated T-lymphocyte dysfunction and increased circulating Interleukine-17 (IL-17) levels. Epigallocatechin-3-gallate (EGCG) specifically inhibits IFN-γ pathways and unlike Janus Kinase 1 and 2 (JAK1/JAK2) inhibitors (tofacitinib, ruxolitinib), EGCG is safer, more cost-effective, and is a topically active agent. Our objective is to test the mode of action of EGCG in vitro and ex vivo using HaCat, Jurkat cell lines, and peripheral blood mononuclear cells (PBMCs) of AA patients and healthy controls (HCs), respectively. Methods: distribution of T helper cells (Th1, Th17), and cytotoxic cells (CD8) in PBMCs isolated from 30 AA patients and 30 HCs was investigated by flowcytomterty. In vitro treatment of HaCat and Jurkat cells with 40 μm EGCG for 48 h was performed to measure the level of phosphorylation of signal transducer and activator of transcription protein STAT1, and replicated in ex vivo model using PBMCs of AA patients. Results: Interestingly, 40 μm EGCG is capable of completely inhibiting phosphorylation of STAT1 after 48 h in HaCat and Jurkat cells and ex vivo in PBMCs of AA patients. Based on QPCR data, the action of EGCG on p-STAT1 seems to be mediated via downregulation of the expression of JAK2 but not JAK1 leading to the inhibition of human leukocyte antigens (HLA-DR and HLA-B) expression probably via IRF-1. On the other hand, AA patients have significantly increased levels of Th1, Th17, and CD8 cells and the production of IFN-γ and IL-17 by PBMCs in AA patients was significantly higher compared to HC; p = 0.008 and p = 0.006, respectively. Total numbers of CD8+ cells were not significantly different between treated and untreated samples. However, CD8+ cells with positive Natural killer group 2 member D (NKG2D) transmembrane receptor (CD8+ NKG2D+ subset) was significantly reduced when PBMCs were treated with 20 μm EGCG for 48 h. Conclusion: These results suggest that EGCG has a synergistic action that inhibits expression of HLA-DR and HLA-B molecules via the IFN-γ pathway to maintain immune privilege in HF; also it reduces CD8+ NKG2D+ subset.
format Online
Article
Text
id pubmed-6313664
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63136642019-06-17 Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients Hamed, Fatma N. McDonagh, Andrew J. G. Almaghrabi, Sarah Bakri, Youssef Messenger, Andrew G. Tazi-Ahnini, Rachid Int J Environ Res Public Health Article Background: Alopecia areata (AA) is associated with Interferon- γ (IFN-γ) mediated T-lymphocyte dysfunction and increased circulating Interleukine-17 (IL-17) levels. Epigallocatechin-3-gallate (EGCG) specifically inhibits IFN-γ pathways and unlike Janus Kinase 1 and 2 (JAK1/JAK2) inhibitors (tofacitinib, ruxolitinib), EGCG is safer, more cost-effective, and is a topically active agent. Our objective is to test the mode of action of EGCG in vitro and ex vivo using HaCat, Jurkat cell lines, and peripheral blood mononuclear cells (PBMCs) of AA patients and healthy controls (HCs), respectively. Methods: distribution of T helper cells (Th1, Th17), and cytotoxic cells (CD8) in PBMCs isolated from 30 AA patients and 30 HCs was investigated by flowcytomterty. In vitro treatment of HaCat and Jurkat cells with 40 μm EGCG for 48 h was performed to measure the level of phosphorylation of signal transducer and activator of transcription protein STAT1, and replicated in ex vivo model using PBMCs of AA patients. Results: Interestingly, 40 μm EGCG is capable of completely inhibiting phosphorylation of STAT1 after 48 h in HaCat and Jurkat cells and ex vivo in PBMCs of AA patients. Based on QPCR data, the action of EGCG on p-STAT1 seems to be mediated via downregulation of the expression of JAK2 but not JAK1 leading to the inhibition of human leukocyte antigens (HLA-DR and HLA-B) expression probably via IRF-1. On the other hand, AA patients have significantly increased levels of Th1, Th17, and CD8 cells and the production of IFN-γ and IL-17 by PBMCs in AA patients was significantly higher compared to HC; p = 0.008 and p = 0.006, respectively. Total numbers of CD8+ cells were not significantly different between treated and untreated samples. However, CD8+ cells with positive Natural killer group 2 member D (NKG2D) transmembrane receptor (CD8+ NKG2D+ subset) was significantly reduced when PBMCs were treated with 20 μm EGCG for 48 h. Conclusion: These results suggest that EGCG has a synergistic action that inhibits expression of HLA-DR and HLA-B molecules via the IFN-γ pathway to maintain immune privilege in HF; also it reduces CD8+ NKG2D+ subset. MDPI 2018-12-15 2018-12 /pmc/articles/PMC6313664/ /pubmed/30558329 http://dx.doi.org/10.3390/ijerph15122882 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hamed, Fatma N.
McDonagh, Andrew J. G.
Almaghrabi, Sarah
Bakri, Youssef
Messenger, Andrew G.
Tazi-Ahnini, Rachid
Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
title Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
title_full Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
title_fullStr Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
title_full_unstemmed Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
title_short Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
title_sort epigallocatechin-3 gallate inhibits stat-1/jak2/irf-1/hla-dr/hla-b and reduces cd8 mkg2d lymphocytes of alopecia areata patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313664/
https://www.ncbi.nlm.nih.gov/pubmed/30558329
http://dx.doi.org/10.3390/ijerph15122882
work_keys_str_mv AT hamedfatman epigallocatechin3gallateinhibitsstat1jak2irf1hladrhlabandreducescd8mkg2dlymphocytesofalopeciaareatapatients
AT mcdonaghandrewjg epigallocatechin3gallateinhibitsstat1jak2irf1hladrhlabandreducescd8mkg2dlymphocytesofalopeciaareatapatients
AT almaghrabisarah epigallocatechin3gallateinhibitsstat1jak2irf1hladrhlabandreducescd8mkg2dlymphocytesofalopeciaareatapatients
AT bakriyoussef epigallocatechin3gallateinhibitsstat1jak2irf1hladrhlabandreducescd8mkg2dlymphocytesofalopeciaareatapatients
AT messengerandrewg epigallocatechin3gallateinhibitsstat1jak2irf1hladrhlabandreducescd8mkg2dlymphocytesofalopeciaareatapatients
AT taziahninirachid epigallocatechin3gallateinhibitsstat1jak2irf1hladrhlabandreducescd8mkg2dlymphocytesofalopeciaareatapatients